Breakthrough study reveals Delcath Systems’ therapy doubles survival for uveal melanoma patients
Delcath Systems, Inc. (Nasdaq: DCTH), a pioneering company in interventional oncology, has announced promising results from a recent independent study evaluating its liver-directed therapy for patients with uveal melanoma. The study, published in the journal Therapeutic Advances in Medical Oncology, is titled “Melanoma-specific survival of patients with uveal melanoma and liver metastases diagnosed between 2005 […]
